Tempus lands in TIME top 10
- TIME put Tempus on its 2026 list of the 10 most influential health and life-science companies, citing its push to blend diagnostics, data and AI. - TIME pointed to Tempus’s Food and Drug Administration-approved xT CDx cancer assay, which reads 648 genes, plus its Ambry Genetics acquisition. - Tempus’s 2025 revenue reached about $1.27 billion after Ambry closed in February 2025. (time.com) (tempus.com) (investors.tempus.com)
TIME named Tempus one of its 10 most influential health and life-science companies of 2026, putting the Chicago precision-medicine company on a new sector list. (time.com) TIME said Tempus stood out for combining cancer testing, clinical data and artificial intelligence tools in one business. The company sells lab tests to guide treatment and software to help doctors and drugmakers use the results. (time.com) (tempus.com) One piece of that model is xT CDx, a Food and Drug Administration-approved companion diagnostic. Tempus says the test analyzes 648 genes in solid tumors, and Food and Drug Administration records show it is approved to help match some patients to targeted drugs. (tempus.com) (fda.gov) Another piece is scale. Tempus completed its acquisition of Ambry Genetics on February 3, 2025, adding hereditary testing and reproductive-health screening to a business that had been centered on oncology. (tempus.com) Tempus’s own financial disclosures show how much that changed the company’s size. In preliminary 2025 results released in February 2026, Tempus said revenue reached about $1.27 billion, up about 83% year over year, with diagnostics revenue of about $955 million. (investors.tempus.com) The company has also kept expanding its software and research tools. In March 2025, Tempus said it acquired Deep 6 AI, a clinical-trial matching platform used by health systems and life-sciences companies. (investors.tempus.com) TIME’s recognition lands as health care investors keep looking for companies that own both regulated tests and the data generated from those tests. Tempus reports a data-and-applications business alongside diagnostics, with about $316 million of preliminary 2025 revenue in that segment. (time.com) (investors.tempus.com) That makes Tempus different from a pure lab company or a pure software vendor. Its pitch is that the same system can generate test results, organize patient records and support drug development work for pharmaceutical companies. (time.com) (tempus.com) The TIME list does not change Tempus’s regulatory status or financial outlook on its own. But it does spotlight a company that spent the last year turning oncology testing, inherited-disease screening and AI software into one larger health-tech platform. (time.com) (tempus.com)
